340 related articles for article (PubMed ID: 35739495)
1. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.
Sapankaew T; Thadanipon K; Ruenroengbun N; Chaiyakittisopon K; Ingsathit A; Numthavaj P; Chaiyakunapruk N; McKay G; Attia J; Thakkinstian A
BMC Nephrol; 2022 Jun; 23(1):223. PubMed ID: 35739495
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
Zhang T; Pope JE
Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
[TBL] [Abstract][Full Text] [Related]
3. To Treat or Not to Treat? Effect of Urate-Lowering Therapy on Renal Function, Blood Pressure and Safety in Patients with Asymptomatic Hyperuricemia: A Systematic Review and Network Meta-Analysis.
Tien YY; Shih MC; Tien CP; Huang HK; Tu YK
J Am Board Fam Med; 2022; 35(1):140-151. PubMed ID: 35039419
[TBL] [Abstract][Full Text] [Related]
4. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
Fan M; Liu J; Zhao B; Wu X; Li X; Gu J; Schlesinger N
Clin Rheumatol; 2021 Feb; 40(2):683-692. PubMed ID: 32654080
[TBL] [Abstract][Full Text] [Related]
5. The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta-analysis of randomized trials.
Zhang S; Xie Q; Xie S; Chen J; Deng Q; Zhong L; Guo J; Yu Y
Pharmacotherapy; 2021 Sep; 41(9):781-791. PubMed ID: 34170566
[TBL] [Abstract][Full Text] [Related]
6. Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis.
Tsukamoto S; Okami N; Yamada T; Azushima K; Yamaji T; Kinguchi S; Uneda K; Kanaoka T; Wakui H; Tamura K
Clin Rheumatol; 2022 Mar; 41(3):911-919. PubMed ID: 34642880
[TBL] [Abstract][Full Text] [Related]
7. The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis.
Barrientos-Regala M; Macabeo RA; Ramirez-Ragasa R; Pestaño NS; Punzalan FER; Tumanan-Mendoza B; Castillo RR
J Cardiovasc Pharmacol; 2020 Oct; 76(4):461-471. PubMed ID: 32675751
[TBL] [Abstract][Full Text] [Related]
8. Allopurinol for chronic gout.
Seth R; Kydd AS; Buchbinder R; Bombardier C; Edwards CJ
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD006077. PubMed ID: 25314636
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of urate-lowering treatments in patients with hyperuricemia: A comprehensive network meta-analysis of randomized controlled trials.
Sun SS; Zhang DH; Shi Y; Lin CJ; Lin JY
J Clin Pharm Ther; 2020 Aug; 45(4):729-742. PubMed ID: 32406077
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials.
Lin YJ; Lin SY; Lin CH; Wang ST; Chang SS
Clin Rheumatol; 2020 May; 39(5):1633-1648. PubMed ID: 31965378
[TBL] [Abstract][Full Text] [Related]
11. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
[TBL] [Abstract][Full Text] [Related]
12. Interventions for tophi in gout.
Sriranganathan MK; Vinik O; Pardo Pardo J; Bombardier C; Edwards CJ
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD010069. PubMed ID: 34379791
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis.
Li S; Yang H; Guo Y; Wei F; Yang X; Li D; Li M; Xu W; Li W; Sun L; Gao Y; Wang Y
Sci Rep; 2016 Sep; 6():33082. PubMed ID: 27605442
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Safety of Urate Lowering Therapies.
Kang EH; Kim SC
Curr Rheumatol Rep; 2019 Jul; 21(9):48. PubMed ID: 31342190
[TBL] [Abstract][Full Text] [Related]
15. Febuxostat for treating chronic gout.
Tayar JH; Lopez-Olivo MA; Suarez-Almazor ME
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008653. PubMed ID: 23152264
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and safety of benzbromarone and febuxostat in gout and hyperuricemia: a systematic review and meta-analysis.
Wu F; Chen L; Du Y
Clin Rheumatol; 2024 May; 43(5):1745-1754. PubMed ID: 38492092
[TBL] [Abstract][Full Text] [Related]
17. Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis.
Castrejon I; Toledano E; Rosario MP; Loza E; Pérez-Ruiz F; Carmona L
Rheumatol Int; 2015 Jul; 35(7):1127-37. PubMed ID: 25519877
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis.
Zhao L; Cao L; Zhao TY; Yang X; Zhu XX; Zou HJ; Wan WG; Xue Y
Chin Med J (Engl); 2020 Apr; 133(8):982-993. PubMed ID: 32106120
[TBL] [Abstract][Full Text] [Related]
19. Uricosuric medications for chronic gout.
Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
Cochrane Database Syst Rev; 2014 Nov; (11):CD010457. PubMed ID: 25392987
[TBL] [Abstract][Full Text] [Related]
20. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
Hu AM; Brown JN
Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]